A study to assess efficacy of citicoline on visual field preservation in patients with glaucoma

You may be able to join if

• 1.Signed written informed consent. 2.Age ≥ 18 years. 3.Eyes with OAG, Pseudoexfoliation and pigmentary glaucoma will be included. 4.Best Corrected Visual Acuity (BCVA) ≥ 0.5 for the study eye. 5.Controlled IOP (≤ 18 mmHg, average of the last 3 measurements in the clinic) in the study eye. 6.Visual field MD not worse than -12 dB at the latest assessment in the clinic for the study eye. 7.Glaucoma definition will be based on VF damage (24-2, any SITA strategy) and spatially congruent glaucomatous changes at the ONH. If both eyes are eligible, the eye with the better MD will be chosen as the study eye. Please refer to the following definitions: • OAG: a reproducible glaucomatous VF defect in at least one eye in reliable VFs (false positive rate ≤15%) with corresponding glaucomatous damage to the Optic Nerve Head (ONH), with an open angle on gonioscopy and in the absence of a retinal, neurological or adnexal condition that could account for the VF loss. • Glaucomatous damage to the Optic Nerve Head: focal or diffuse loss of neuro-retinal tissue identified by the investigator by means of ophthalmoscopy AND/OR fundus photographs AND/OR Optical Coherence Tomography imaging. • Reproducible glaucomatous VF defect: a Glaucoma Hemifield Test (GHT) outside normal limits AND a cluster of 3 or more locations, 2 of which are depressed on the pattern deviation plot at a P value of <5% and 1 of which is depressed at a P value of <1%, on at least 2 consecutive reliable fields. At least 1 common location in the cluster should be depressed at <5% in the 2 consecutive VFs. • Definition of a VF cluster: each depressed location in the clusters should be adjacent to at least one other depressed location. 8.Women of childbearing potential (WOCBP) willing to use a highly effective method of contraception for up to 90 days after the last dose of treatment.